A Randomized, Open Label, Single Dose, 4-period Replicate Crossover Clinical Trial to Evaluate the Pharmacokinetic Characteristics and Safety After Administration of a Fixed-dose Combination Drug of HCP2201 and Co-administration of RLD2205 and RLD2206 in Healthy Male Volunteers Under Fasting Conditions
Latest Information Update: 08 Mar 2024
At a glance
- Drugs HCP 2201 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Hanmi Pharmaceutical
- 20 Sep 2023 Status changed from not yet recruiting to completed.
- 01 Mar 2023 New trial record